Key statistics dashboard for Sagimet Biosciences Inc. (SGMT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Stock Data
| Price | $10.46 |
| Market Cap | $341M |
| Enterprise Value | $176.8M |
| Beta | 3.21 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -8.17 |
| Price / Book | 2.17 |
| P/S | 0.00 |
| EV/EBITDA | -3.56 |
| EV/Sales | 0.00 |
| EV/FCF | -4.28 |
| P/FCF | -8.25 |
| Earnings Yield | -8.47% |
| FCF Yield | -12.12% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -31.96% |
| Return on Assets | -17.87% |
| Return on Invested Capital | -20.39% |
| Return on Capital Employed | -20.40% |
Financial Health
| Current Ratio | 45.02 |
| Quick Ratio | 45.02 |
| Cash Ratio | 30.61 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.74% |
| Net Debt / EBITDA | 3.30 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 4.82 |
| Cash per share | 4.52 |
| FCF per share | -0.78 |
| Tangible Book Value per share | 4.82 |
| Dividend per share | 0.00 |
Related companies: ACHV · ARCT · ASMB · AVIR · FHTX · HUMA · IMRX
Explore sector: Healthcare · Biotechnology
More sections of SGMT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks